Tobin C. Schilke
Overview
Tobin C. Schilke received an average of $2M in total compensation, including $331K in salary, at Revance Therapeutics from 2018 to 2021. Tobin Schilke also received $2M at Achaogen in 2017.
Source: SEC filings on March 24, 2022, March 24, 2021, March 26, 2020, March 25, 2019, and April 18, 2018.
Related executives
We found 17 more executives who work or worked at Revance Therapeutics and Achaogen.
Mark Foley
Revance Therapeutics
Chief Executive Officer
Dustin Sjuts
Revance Therapeutics
President
Aubrey Rankin
Revance Therapeutics
Former President, Innovation & Technology
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
Dwight Moxie
Revance Therapeutics
General Counsel
L Browne
Revance Therapeutics
Chief Executive Officer
Caryn McDowell
Revance Therapeutics
General Counsel
Todd Zavodnick
Revance Therapeutics
Former Chief Commercial Officer and President, Aesthetics & Therapeutics
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019